New vaccine targets rare liver Cancer's genetic weakness
NCT ID NCT06789198
First seen Feb 16, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This early-stage trial tests a peptide vaccine designed to train the immune system to attack cancer cells that carry a specific genetic change (DNAJB1-PRKACA fusion). It is for people with fibrolamellar liver cancer or other tumors with this same change, who have already achieved complete remission. The study focuses on safety and whether the vaccine can stimulate a targeted immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Tuebingen
RECRUITINGTübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsklinikum Tübingen, Kinderheilkunde I
NOT_YET_RECRUITINGTübingen, 72076, Germany
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.